{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:20:09Z","timestamp":1791908409778,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to evaluate the prognostic significance of baseline laboratory parameters and inflammatory indices in patients with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in the second line and beyond, potentially aiding personalized patient management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study analyzed data from 83 female patients with mTNBC who initiated SG therapy at four Polish oncology centers between August 2021 and September 2024. Hematological parameters\u2014white blood cell count (WBC), hemoglobin (Hb), platelets (Plt) and inflammatory indices\u2014neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were assessed at baseline and before each dose of first four SG cycles. Median progression-free survival (mPFS) and overall survival (mOS) were estimated, and, as the\u00a0primary objectives, associations between baseline laboratory variables and survival outcomes were assessed using multivariate Cox regression models (\n                      <jats:italic>\u03b1<\/jats:italic>\n                      \u2009=\u20090.05). Secondary objectives included assessing their associations with patient and disease characteristics, prior treatment lines, and adverse events (AEs), which were classified using the National Cancer Institute Common Terminology Criteria for AEs (NCI\u2010CTCAE), version 5.0.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mPFS was 4.07\u00a0months (95% CI 3.05\u20136.18), while the mOS was 8.01\u00a0months (95% CI 6.05\u20139.75). Lower baseline Hb was significantly associated with shorter PFS (HR\u2009=\u20090.82,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) but not OS. Elevated baseline NLR predicted worse OS (HR\u2009=\u20091.18,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), while PLR and SII lacked prognostic significance. Changes in blood parameters within initial four SG cycles showed no significant correlations with survival outcomes. Furthermore, baseline hematological markers and inflammatory indices showed no significant association with clinical characteristics, prior therapy lines, tumor burden, or the occurrence and severity of AEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline Hb and NLR were identified as independent prognostic biomarkers in patients with mTNBC receiving SG treatment, predicting PFS and OS, respectively. Other inflammatory indices (PLR, SII) did not demonstrate prognostic relevance. Prospective validation in larger cohorts is essential to confirm these findings and potentially guide personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-025-07825-0","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:34:35Z","timestamp":1758983675000},"page":"397-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis"],"prefix":"10.1007","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5864-0877","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Pieni\u0105\u017cek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Las-Jankowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-2068","authenticated-orcid":false,"given":"Jakub","family":"Wronowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"\u0141acko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-9625","authenticated-orcid":false,"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"7825_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"7825_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","volume":"9","author":"F Kassam","year":"2009","unstructured":"Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9:29\u201333","journal-title":"Clin Breast Cancer"},{"key":"7825_CR3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/fon-2020-1021","volume":"17","author":"KE Skinner","year":"2021","unstructured":"Skinner KE, Haiderali A, Huang M, Schwartzberg LS (2021) Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer. Future Oncol 17:931\u2013941","journal-title":"Future Oncol"},{"key":"7825_CR4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529\u20131541","journal-title":"N Engl J Med"},{"key":"7825_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09112-9","author":"S Takamizawa","year":"2022","unstructured":"Takamizawa S, Shimoi T, Satomi-Tsushita N et al (2022) Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-021-09112-9","journal-title":"BMC Cancer"},{"key":"7825_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036315","volume":"102","author":"J Xie","year":"2023","unstructured":"Xie J, Guo Z, Zhu Y, Ma M, Jia G (2023) Peripheral blood inflammatory indexes in breast cancer: a review. Medicine 102:E36315","journal-title":"Medicine"},{"key":"7825_CR7","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","volume":"130","author":"D Hanna","year":"2024","unstructured":"Hanna D, Merrick S, Ghose A et al (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer 130:1916\u20131920","journal-title":"Br J Cancer"},{"key":"7825_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00242","author":"S Alaklabi","year":"2024","unstructured":"Alaklabi S, Roy AM, Zagami P et al (2024) Real-World clinical outcomes with Sacituzumab govitecan in metastatic triple-negative breast cancer. JCO Oncol Pract. https:\/\/doi.org\/10.1200\/OP.24.00242","journal-title":"JCO Oncol Pract"},{"key":"7825_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1362641","author":"R Caputo","year":"2024","unstructured":"Caputo R, Buono G, Piezzo M et al (2024) Sacituzumab govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1362641","journal-title":"Front Oncol"},{"key":"7825_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","volume":"31","author":"A De Moura","year":"2024","unstructured":"De Moura A, Loirat D, Vaillant S et al (2024) Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut curie hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer 31:572\u2013580","journal-title":"Breast Cancer"},{"key":"7825_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-024-00307-1","author":"M P\u00fcsk\u00fcll\u00fco\u011flu","year":"2024","unstructured":"P\u00fcsk\u00fcll\u00fco\u011flu M, Pieni\u0105\u017cek M, Las-Jankowska M et al (2024) Sacituzumab govitecan for second and subsequent line palliative treatment of patients with triple-negative breast cancer: a Polish real-world multicenter cohort study. Oncol Ther. https:\/\/doi.org\/10.1007\/s40487-024-00307-1","journal-title":"Oncol Ther"},{"key":"7825_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231200454","author":"M Reinisch","year":"2023","unstructured":"Reinisch M, Bruzas S, Spoenlein J et al (2023) Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359231200454","journal-title":"Ther Adv Med Oncol"},{"key":"7825_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(03)00103-4","author":"SJP Van Belle","year":"2004","unstructured":"Van Belle SJP (2004) What is the value of hemoglobin as a prognostic and predictive factor in cancer? Eur J Cancer Suppl. https:\/\/doi.org\/10.1016\/S1359-6349(03)00103-4","journal-title":"Eur J Cancer Suppl"},{"key":"7825_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102631","author":"L Wang","year":"2020","unstructured":"Wang L, Simons DL, Lu X, Tu TY, Avalos C, Chang AY, Dirbas FM, Yim JH, Waisman J, Lee PP (2020) Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102631","journal-title":"EBioMedicine"},{"key":"7825_CR15","first-page":"167","volume":"36","author":"L Li","year":"2021","unstructured":"Li L, Wang J, Meng S, Li Z, Huang Z, Sun J, Wang G, Luo F, Yang K (2021) Peripheral blood leukocytes and platelets serve as prognostic factors in breast cancer. Cancer Biother Radiopharm 36:167\u2013173","journal-title":"Cancer Biother Radiopharm"},{"key":"7825_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/289563","volume":"2013","author":"A Stravodimou","year":"2013","unstructured":"Stravodimou A, Voutsadakis IA (2013) Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer. Int J Breast Cancer 2013:1\u20136","journal-title":"Int J Breast Cancer"},{"key":"7825_CR17","doi-asserted-by":"publisher","unstructured":"Shen X, Xiang M, Tang J et al (2024) Evaluation of peripheral blood inflammation indexes as prognostic markers for colorectal cancer metastasis. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-024-68150-y","DOI":"10.1038\/s41598-024-68150-y"},{"key":"7825_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0794-1","author":"JL Ethier","year":"2017","unstructured":"Ethier JL, Desautels D, Templeton A, Shah PS, Amir E (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-016-0794-1","journal-title":"Breast Cancer Res"},{"key":"7825_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165133","author":"B Chen","year":"2016","unstructured":"Chen B, Dai D, Tang H, Ai X, Chen X, Zhang X, Li Z, Xie X (2016) Pretreatment hematocrit is superior to hemoglobin as a prognostic factor for triple negative breast cancer. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0165133","journal-title":"PLoS ONE"},{"key":"7825_CR20","volume-title":"Neutrophil-lymphocyte ratio in different stages of breast cancer","author":"MR Keramati","year":"2017","unstructured":"Keramati MR, Elyasinia F, Keramati MR et al (2017) Neutrophil-lymphocyte ratio in different stages of breast cancer. Acta Medica Iranica, Tehran"},{"key":"7825_CR21","unstructured":"Minister of Health in Poland (2024) Announcements of the Minister of Health\u2014List of reimbursed medications. https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych. Accessed 19 Jun 2025"},{"key":"7825_CR22","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"7825_CR23","unstructured":"Summary of Product Characteristics of Sacitzumab govitecan (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trodelvy-epar-product-information_en.pdf. Accessed 19 Jun 2025"},{"key":"7825_CR24","unstructured":"Cancer Institute N (2017) Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0."},{"key":"7825_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjmed.2003.12.008","volume":"116","author":"K Knight","year":"2004","unstructured":"Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116:11\u201326","journal-title":"Am J Med"},{"key":"7825_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1634\/theoncologist.9-90005-10","volume":"9","author":"P Vaupel","year":"2004","unstructured":"Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. Oncologist 9:10\u201317","journal-title":"Oncologist"},{"issue":"4","key":"7825_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1385\/MO:18:4:243","volume":"18","author":"P Vaupel","year":"2001","unstructured":"Vaupel P, Thews O, Hoeckel M (2001) Introduction treatment resistance of solid tumors role of hypoxia and anemia. Med Oncol 18(4):243\u2013259","journal-title":"Med Oncol"},{"key":"7825_CR28","first-page":"e12549","volume-title":"Association of pre-treatment hemoglobin levels with survival outcomes among Indian women with triple negative breast cancer","author":"H Krishna Raju Sagiraju","year":"2022","unstructured":"Krishna Raju Sagiraju H, Gogia A, Kumar Sharma R, Deo S, Sharma D, Gupta R (2022) Association of pre-treatment hemoglobin levels with survival outcomes among Indian women with triple negative breast cancer. ASCO Publications, Alexandria, p e12549"},{"key":"7825_CR29","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P4-05-02","volume":"31","author":"M Puskulluoglu","year":"2025","unstructured":"Puskulluoglu M, Pieniazek M, Streb J et al (2025) Abstract P4\u201305-02: Strategies for premedication and neutropenia prophylaxis in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights. Clin Cancer Res 31:P4\u201305\u201302","journal-title":"Clin Cancer Res"},{"key":"7825_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.breast.2018.12.014","volume":"44","author":"V Graziano","year":"2019","unstructured":"Graziano V, Grassadonia A, Iezzi L et al (2019) Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast 44:33\u201338","journal-title":"Breast"},{"key":"7825_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9503025","author":"M Zhang","year":"2017","unstructured":"Zhang M, Huang XZ, Song YX, Gao P, Sun JX, Wang ZN (2017) High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: a meta-analysis. Biomed Res Int. https:\/\/doi.org\/10.1155\/2017\/9503025","journal-title":"Biomed Res Int"},{"key":"7825_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01563-7","author":"H Onagi","year":"2022","unstructured":"Onagi H, Horimoto Y, Sakaguchi A et al (2022) High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-022-01563-7","journal-title":"Breast Cancer Res"},{"issue":"43","key":"7825_CR33","doi-asserted-by":"publisher","first-page":"75381","DOI":"10.18632\/oncotarget.18856","volume":"8","author":"J-H Zhong","year":"2017","unstructured":"Zhong J-H, Huang D-H, Chen Z-Y (2017) Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget 8(43):75381","journal-title":"Oncotarget"},{"key":"7825_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235936","author":"E Sakach","year":"2022","unstructured":"Sakach E, Sacks R, Kalinsky K (2022) Trop-2 as a therapeutic target in breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14235936","journal-title":"Cancers (Basel)"},{"key":"7825_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01261-0","author":"J Lai","year":"2024","unstructured":"Lai J, Deng S, Cao J, Ren Y, Xu Z, Qi X, Xu M, Liao N (2024) Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapy. Discov Oncol. https:\/\/doi.org\/10.1007\/s12672-024-01261-0","journal-title":"Discov Oncol"},{"key":"7825_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061744","author":"P Lombardi","year":"2023","unstructured":"Lombardi P, Filetti M, Falcone R, Altamura V, ParoniSterbini F, Bria E, Fabi A, Giannarelli D, Scambia G, Daniele G (2023) Overview of trop-2 in cancer: from pre-clinical studies to future directions in clinical settings. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15061744","journal-title":"Cancers (Basel)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07825-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07825-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07825-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:48:25Z","timestamp":1762174105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07825-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7825"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07825-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was approved by the ethical committees of the Maria Sk\u0142odowska-Curie National Research Institute of Oncology in Poland, including the Warsaw Branch (approval number 21\/2024, issued on February 22, 2024) and the Krak\u00f3w Branch (approval number 2\/2023, issued on April 18, 2023). All activities involving human participants adhered to the ethical guidelines established by the institutional review board, the principles of the 1964 Helsinki Declaration, and subsequent updates or equivalent ethical frameworks. Before initiating SG treatment under the national reimbursement program, all patients provided informed consent following institutional protocols. The ethical committee concluded that additional informed consent was not necessary for the retrospective data collection. All procedures complied with applicable ethical guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}